Shareholders of Neimeth International Pharmaceuticals Plc have approved a major capital restructuring scheme that will reduce the company’s share premium account from N2.38 billion to N390.02 million and transfer N1.99 billion to its retained earnings reserve.
The approval was granted at a Court-Ordered Meeting held virtually, where shareholders backed up the Scheme of Arrangement aimed at strengthening the company’s balance sheet and enhancing financial flexibility for future operations.
The restructuring forms part of Neimeth’s broader corporate reorganisation efforts as the pharmaceutical firm seeks to improve its capital structure and position itself for long-term growth.
The approved scheme represents a balance sheet restructuring exercise rather than an injection of new capital into the company.
The move is widely regarded as a capital structure optimization strategy aimed at unlocking trapped reserves within the company’s equity base without altering total shareholders’ funds.
Analysts say the restructuring could improve Neimeth’s financial presentation and strengthen its ability to pursue future growth initiatives.
In addition, the company’s solicitors were mandated to seek court sanctions for the scheme and obtain all incidental orders necessary to give legal effect to the restructuring.
Corporate restructuring exercises involving share premium reductions are commonly deployed by companies seeking to optimise their balance sheets, improve reserve flexibility, and strengthen long-term financial positioning without issuing new shares or raising additional capital.
The restructuring remains subject to final regulatory and court approvals before it can be fully implemented.
